Post by Journal of Dermatology for NPs & PAs

When Maui, HI-based Dermatologist Dr. George Martin first started out in 1985, #vitiligo was considered an orphan disease, but times have changed. “The evolution over the past 40-plus years has been nothing but astounding,” he says in this episode of Prescribing Hope in Vitiligo. Calling the development and approval of topical ruxolitinib (Opzelura, Incyte) for vitiligo, a “total game-changer” and proof that the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway was a major player in the pathogenesis of vitiligo, Dr. Martin discusses the importance of managing patient expectations during the repigmentation process. https://lnkd.in/eNKAafqJ